Plasma calprotectin and its association with cardiovascular disease manifestations, obesity and the metabolic syndrome in type 2 diabetes mellitus patients

BMC Cardiovascular Disorders

Research Article

Jordi Dahl¹  Mikael Kjær Poulsen²  Mads Nybo³  Lars Melholt Rasmussen³  Lise Pedersen³  Jan Erik Henriksen⁴ 

[1] Department of Cardiology, Odense University Hospital, Sdr. Blvd 29, 5000, Odense C, Denmark;Department of Cardiology, Sygehus Lillebælt, Kabbeltoft 25, 7100, Vejle, Denmark;Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Sdr. Boulevard 29, 5000, Odense C, Denmark;Department of Endocrinology, Diabetes Research Center, Odense University Hospital, Sdr. Blvd 29, 5000, Odense C, Denmark;

关键词: Calprotectin;    MRP8/14;    Cardiovascular disease;    Inflammation;    Type 2 diabetes;    Obesity;    Metabolic syndrome;    Automated assay;    Reference range;   

DOI  :  10.1186/1471-2261-14-196

 received in 2014-09-01, accepted in 2014-12-16,  发布年份 2014

来源: Springer

【 摘 要 】

BackgroundPlasma calprotectin is a potential biomarker of cardiovascular disease (CVD), insulin resistance (IR), and obesity. We examined the relationship between plasma calprotectin concentrations, CVD manifestations and the metabolic syndrome (MetS) in patients with type 2 diabetes mellitus (T2DM) in order to evaluate plasma calprotectin as a risk assessor of CVD in diabetic patients without known CVD.MethodsAn automated immunoassay for determination of plasma calprotectin was developed based on a fecal Calprotectin ELIA, and a reference range was established from 120 healthy adults. Plasma calprotectin concentrations were measured in 305 T2DM patients without known CVD. They were screened for carotid arterial disease, peripheral arterial disease (PAD), and myocardial ischemia (MI) by means of carotid artery ultrasonography, peripheral ankle and toe systolic blood pressure measurements, and myocardial perfusion scintigraphy.ResultsThe reference population had a median plasma calprotectin concentration of 2437 ng/mL (2.5-97.5% reference range: 1040–4262 ng/mL). The T2DM patients had significantly higher concentrations (3754 ng/mL, p < 0.0001), and within this group plasma calprotectin was significantly higher in patients with MetS (p < 0.0001) and also in patients with autonomic neuropathy, PAD, and MI compared with patients without (p < 0.001, p = 0.021 and p = 0.043, respectively). Plasma calprotectin was by linear regression analysis found independently associated with BMI, C-reactive protein, and HDL cholesterol. However, plasma calprotectin did not predict autonomic neuropathy, PAD, MI or CVD when these variables entered the multivariable regression analysis as separate outcome variables.ConclusionT2DM patients had higher concentrations of plasma calprotectin, which were associated with obesity, MetS status, autonomic neuropathy, PAD, and MI. However, plasma calprotectin was not an independent predictor of CVD, MI, autonomic neuropathy or PAD.Trial registration numberNCT00298844

【 授权许可】

CC BY   
© Pedersen et al.; licensee BioMed Central. 2014